Avastin

Source: sanfrancisco.bizjournals.com --- 7 days ago
Genentech Inc. and OSI Pharmaceuticals Inc. said a combination of the cancer-fighting drugs Tarceva and Avastin does not show an overall increase in survival rates for lung cancer patients. (DNA) (OSIP) ...

Source: www.medicalnewstoday.com --- 7 days ago
Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. ...

Source: www.webwire.com --- 7 days ago
Phase III data shows evidence of potential benefit for patients with advanced lung cancer - - Roche today announced topline results from the phase III BeTa Lung study investigating the addition of Avas... [WebWire - Monday, October 06, 2008] ...

Source: www.libn.com --- 7 days ago
...

Source: www.fiercepharma.com --- 7 days ago
A high-powered drug combo didn't make the grade in a new lung cancer trial. Combining Genentech's Avastin and OSI Pharmaceuticals' Tarceva didn't boost survival for patients who had not responded to chemotherapy, failing the trial's primary endpoint. Release | Report ...

Source: www.emaxhealth.com --- 7 days ago
A clinical trial looking at combination of two popular lung cancer drugs Tarceva and Avastin showed that the drugs given together for lung cancer treatment do not increase survival rates. Tarceva is marketed by Genentech and Avastin by Roche. Both drugs are already widely available in US and Europe as lung cancer treatment. Both drugs belong to a series of drugs under targeted therapies – innovative drugs that are also called ‘smart bombs’ because they are able to differ cancerous cells from healthy ones and kill those affected by the disease. read more ...

Source: www.streetinsider.com --- 7 days ago
Visit StreetInsider.com at http://www.streetinsider.com/FDA/Genentech+and+OSI+Phama+Said+AvastinTarceva+Combo+Fails+As+Second-Line+Treatment+For+Lung+Cancer/4044343.html for the full story. ...

Source: www.genengnews.com --- 7 days ago
...

Source: sci.tech-archive.net --- 4 days ago
Summary: decides to fund colorectal cancer drug - Avastin ... REGINA -- Colorectal cancer patients in Saskatchewan welcomed news ... The provincial government said it will pick up the tab for Avastin. ... The drug has been available to patients in Saskatchewan, ... ...

Source: bmartinmd.com --- 5 days ago
Targeted, combination therapy in cancer sure seems like a good idea. However, the addition of the anti-angiogenesis mAb bevacizumab (Avastin; Genentech) to the EGFR inhibitor erlotinib (Tarceva; Genentech/OSI) did not improve overall survival in patients with platinum-refractory non-small cell lung cancer (NSCLC).... ...

Source: news.yahoo.com --- 7 days ago
Reuters - Roche Holding AG and Genentech Inc said on Monday a study into the benefits of combining their Tarceva and Avastin drugs for lung cancer patients did not show an increase in overall survival. ...

Source: www.moreover.com --- 7 days ago
By Emma Thomasson and Ben Hirschler ZURICH/LONDON (Reuters) - Roche Holding AG and Genentech Inc said on Monday a study into the benefits of combining their Tarceva and Avastin drugs for lung cancer patients did not show an increase in overall ...

Source: www.moreover.com --- 8 days ago
ANTI-cancer drug Avastin is unaffordable and pharmaceutical giants could do more to help, experts say Breast Cancer Network Australia policy manager Michelle Marven said that at $2500 to $5700 for a course the drug, which is claimed to cut off a ...

Source: www.marketwatch.com --- 6 days ago
Shares of Genentech Inc. and OSI Pharmaceuticals fall after the companies reported disappointing results from a study that tested Genentech’s top-selling oncology drug Avastin with OSI’s Tarceva in the treatment of advanced lung cancer. ...

Source: blogs.wsj.com --- 6 days ago
Traditional chemotherapy relies on multi-drug combinations, but combining Avastin and Tarceva to treat lung cancer was no better than using Tarceva alone, a Genentech study found. ...

Source: www.streetinsider.com --- 7 days ago
StreetInsider.com Morning Movers: National City Corporation (NYSE: NCC) 23% LOWER; Fitch downgrade Arcelor Mittal (NYSE: MT) 13% LOWER; Deutsche Bank downgrade OSI Pharmaceuticals (Nasdaq: OSIP) 11% LOWER; Genentech, Inc. (NYSE: DNA) and OSI Pharmaceuticals announced that a randomized Phase III study (BeTa Lung) evaluating Avastin in combination with Tarceva in patients with advanced non-small cell lung cancer whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo. Citigroup Inc. (NYSE: C) 7% LOWER; Battles Wells Fargo for Wachovia Standard Pacific (NYSE: SPF) 7% LOWER; JP Morgan downgrades to Underweight Netflix Inc. ...

Source: www.247wallst.com --- 7 days ago
OSI Pharmaceuticals Inc. (NASDAQ: OSIP) is getting hit hard in early trading this morning.  The biotech has released data showing that a Phase III trial of Genentech's (NYSE: DNA) Avastin combined with Tarceva in certain patients with advanced non-small-cell lung cancer did not meet the primary endpoint of increasing overall survival compared with Tarceva plus placebo. The study assessed cancer patients who had progressed after going through platinum based chemotherapy treatments.   One note that the company made was that it did show evidence of clinical activity and it saw improvements in secondary endpoints of progression-free survival and response rate when Avastin was added to Tarceva compared to Tarceva alone. OSI Pharma is getting slammed in the early morning trading on an already tough morning for stocks.  Shares are down 13% at $39.77 on about 6,500 shares.  Its 52-week trading range is $32.10 to $53.71. Jon C. Ogg October 6, 2008 ...